Janssen: European Commission approves PONVORYTM ? (ponesimod), a Once Daily, Oral Therapy for the Treatment of Adults with Relapsing Forms of Multiple Sclerosis with Active Disease Defined by Clinical or Imaging Features
(0) The pivotal Phase 3 OPTIMUM trial showed treatment with ponesimod led to a 30.5 percent reduction in annual relapse rate (p1 The OPTIMUM trial is the first of its kind to compare head-to-head two oral disease modifying treatments (DMTs) in RMS Approval follows more than 10 years of cumulative data from Phase 2 and Phase 3 studies demonstrating ponesimod's efficacy and safety 1,2,3 Approval builds on Janssen's deep-rooted history in neuroscience and reinforces Company commitment to addressing unmet needs for neurological conditions like MS Janssen, the Pharmaceutical Companies of Johnson J...
Source: finanznachrichten.de
